- Phase 1a dose escalation study of ivonescimab (AK112 SMT112), an anti . . .
Here, we report the first-in-human, phase 1a study of ivonescimab in patients with advanced solid tumors Methods: Patients with advanced solid tumors were treated with ivonescimab 0 3, 1, 3, 10, 20 or 30 mg kg intravenously every 2 weeks using a 3+3+3 dose escalation design
- Phase 1a dose escalation study of ivonescimab (AK112 SMT112), an anti . . .
In this study, we evaluated the safety and efficacy of ivonescimab, a novel anti-PD-1 VEGF-A bispecific antibody, in patients with advanced solid tumors Two DLTs were observed out of 6 patients at 30 mg kg every 2 weeks
- A phase I study of AK112, a bispecific antibody that targets PD-1 and . . .
Methods: This is a Phase 1a 1b, first-in-human, multicenter, open-label study in patients with advanced or metastatic solid tumor that is refractory relapsed to standard therapies The primary objective is to assess safety, tolerability and DLTs; and to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose of AK112
- Phase 1a dose escalation study of ivonescimab - ProQuest
Ivonescimab (AK112) is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously This is the first-in-human phase 1a study demonstrating that ivonescimab is safe and tolerable
- A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and . . .
Introduction: This study (HARMONi-5) aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor) as first- or second-line monotherapy in patients with advanced immunotherapy-naive NSCLC
- Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of . . .
We report the safety, pharmacokinetics (PK), and pharmacodynamics (PD) profiles of ivonescimab in patients suffered from advanced solid tumors Methods: A multicenter, open-label, dose-escalation, phase I study was conducted in five hospitals in China Ivonescimab was used as a monotherapy
- Phase 3 Study of Ivonescimab (AK112) vs. - akesobio. com
Ivonescimab (AK112) is a novel bispecific antibody against PD-1 and VEGF and has shown promising clinical efficacy and safety as front-line therapy for patients with PD-L1-positive aNSCLC in the phase 2 study (AK112-202)3
- Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as . . .
This study aimed to evaluate the safety and tolerance of ivonescimab combined with etoposide and carboplatin as first-line treatment in patients with extensive-stage SCLC and to explore the primary efficacy of this regimen
|